Edition:
United States

People: Impax Laboratories Inc (IPXL.OQ)

IPXL.OQ on NASDAQ Stock Exchange Global Select Market

23.00USD
22 Sep 2017
Change (% chg)

$-0.80 (-3.36%)
Prev Close
$23.80
Open
$23.70
Day's High
$23.90
Day's Low
$22.75
Volume
457,267
Avg. Vol
392,886
52-wk High
$27.16
52-wk Low
$7.80

Schlossberg, Mark 

Mr. Mark A. Schlossberg Esq is Senior Vice President, General Counsel, Corporate Secretary of Impax Laboratories Inc. He has served as our Senior Vice President, General Counsel and Corporate Secretary since May 2011. Since September 2015, he has served on the board of directors of Immunocelluar Therapeutics Ltd (NYSE: IMUC), a clinical-stage company focused on the development of immune-based therapies for the treatment of brain and other cancers based in Los Angeles, California. Prior to joining us, he served as Vice President, Associate General Counsel of Amgen Inc. human therapeutics biotechnology company, from September 2004 to May 2011. Prior to joining Amgen, he held legal and business positions at Medtronic, Inc. a medical technology company and legal positions at Diageo plc, RJR Nabisco, Inc. and Mudge Rose Guthrie Alexander & Ferdon. He earned a Bachelor of Sciences in business administration, finance from the University of Southern California and a Juris Doctor degree from Emory University.

Basic Compensation

Total Annual Compensation, USD 515,045
Restricted Stock Awards, USD 727,016
Long-Term Incentive Plans, USD --
All Other, USD 749,419
Fiscal Year Total, USD 1,991,480

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Robert Burr

389,374

Paul Bisaro

--

Bryan Reasons

2,248,520

Douglas Boothe

2,499,380

Michael Nestor

2,000,560

Mark Schlossberg

1,991,480
As Of  30 Dec 2016